Recently, a case of ICI-induced polymyalgia rheumatica controlled by the MEK inhibitor cobimetinib showed the in vivo anti-inflammatory potential of targeting the MAPK signaling pathway [39]. This evidence concerns the gene MAP2K7 and Myalgia.